Alembic Pharmaceuticals Ltd Q4 FY2026 Concall Summary

Key Takeaways

• Execution-led pivot, margin ambition set: Management is consciously shifting to an execution-led model focused on portfolio quality, asset utilization, and cost discipline, while targeting 20% EBITDA margins over a 2-3 year period.
• U.S. branded business enters investment phase: The launch of Pivya in February created a margin drag that will persist for another quarter or two, with a turnaround expected only by the end of FY27.
• R&D spike is a one-off, not a new run-rate: Q4 R&D jumped to 11% of sales due to expensive peptide and complex development batches; management expects a return to ~9% of revenue in FY27.
• Facility utilization improving, drag fading: F2 and F3 facilities are working at much higher occupancy, with the F3 ophthalmic line already at full capacity and under expansion; the remaining unabsorbed overhead is called "too small a drag."
• What to watch next quarter: Whether the promised R&D normalization to ~9% materializes, any early prescription metrics on Pivya, and the pace of India business acceleration toward market growth.

Strategic Pivot & Margin Ambition

• Execution-led model: Management is consciously moving toward higher focus on portfolio quality, launches with asset utilization, stronger cost and working capital discipline, and selective investments in platforms.
• Margin target set: The company is targeting 20% EBITDA margins over a 2-3 year period, with improvement expected in FY27 driven by operating leverage from the core business, though no formal FY27 guidance was given.
• Operating leverage offset: Margin improvement from the core business is expected to provide enough headroom to absorb the launch-phase costs of the U.S. branded business.
• Net working capital rise: Driven by receivables not yet due, not a deterioration in collection quality.

Pranav Amin: "We are consciously moving towards a more execution-led strategic model. This means higher focus on quality of portfolio and launches with asset utilization, stronger cost and working capital discipline and selective investments in platforms."

U.S. Branded Business: Pivya Launch & Investment Phase

• Pivya launched February 2026: The drug was launched under the Alembic Therapeutics umbrella with an initial field force focused on high-prescription territories for UTIs.
• Margin drag quantified in duration, not amount: Management expects another quarter or two of drag from launch costs before the franchise turns around, with a decent contribution visible only by the end of FY27.
• Calibrated, not rapid, scale: The objective is to build a credible and sustainable specialty platform over time, supported by selective product additions and in-licensing opportunities, not rapid revenue scale.
• No prescription data shared: Management declined to provide any post-launch metrics, saying it will be another quarter or two before they are comfortable sharing data.

Pranav Amin: "I expect another quarter or two of the drag coming, by the end of the year, we should start seeing a decent contribution. And last quarter is when we see it starting to turn around."

R&D: Q4 Spike, Normalization & Productivity

• Q4 R&D at 11% was an outlier: The spike was driven by selective complex and peptide development activities with more expensive batches conducted, including NCE-1/5 work. Management expects R&D to return to ~9% of revenue for FY27.
• FY27 R&D budget: Likely around ₹750–₹800 crores, calibrated toward higher-value opportunities including NCE-1, First-to-File, and Day 1 molecules.
• IRR thresholds have fallen: Development costs have risen and returns are lower than pre-2020 levels, which is why R&D was tapered. Management still sees opportunities and measures each project by IRR, though the threshold has come down.
• Peptide capex complete: All capex for peptide API and formulation is done, housed within an existing facility; management declined to disclose the amount. One peptide launch is expected at the end of this quarter, with a 5-6 product portfolio in development.

Pranav Amin: "As it's getting more competitive, development cost is also getting more expensive. So the threshold IRR has come down, but we still see some opportunities, and that's how we're measuring."

Facility Utilization & Capacity

• F2 and F3 occupancy rising: Both facilities are working at much higher occupancy levels than before, with more volume coming through.
• F3 ophthalmic line at full capacity: The line is "chock-a-block," and an expansion is already underway. The other two F3 lines are at 40% and 60% capacity utilization.
• F2 injectable and OSD lines: Working at decent levels; the unabsorbed OSD overhead is described as "too small a drag in the overall scheme of things."
• Contract manufacturing and licensing: Already started for F2/F3 facilities, with partial contribution expected in FY27.
• Indore facility: Fully operational with capacity utilization improving.

Business Segment Performance & Outlook

• API pricing power: The API business sells at premium prices due to compliance and supply chain resilience, and does not compete at the bottom level with Chinese producers. Solvent price increases have not been passed on, cushioned by higher inventory levels.

Pranav Amin: "We do sell APIs at a much higher price. We don't compete at the bottom level whether -- for lack of a better -- whether Chinese or the are dropping prices. So we do have premium prices on the markets."

Guidance & Commitments

Key Metrics